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Abstract
Background: Though rooted in genomic expression studies, pathway analysis for genome-wide association studies
(GWAS) has gained increasing popularity, since it has the potential to discover hidden disease pathogenic
mechanisms by combining statistical methods with biological knowledge. Generally, algorithms or programs
proposed recently can be categorized by different types of input data, null hypothesis or counts of analysis stages.
Due to complexity caused by SNP, gene and pathway relationships, re-sampling strategies like permutation are
always utilized to derive an empirical distribution for test statistics for evaluating the significance of candidate
pathways. However, evaluation of these algorithms on real GWAS datasets and real biological pathway databases
needs to be addressed before we apply them widely with confidence.
Findings: Two algorithms which use summary statistics from GWAS as input were implemented in KGG, a novel
and user-friendly software tool for GWAS pathway analysis. Comparisons of these two algorithms as well as the
other five selected algorithms were conducted by analyzing the WTCCC Crohn’s Disease dataset utilizing the
MsigDB canonical pathways. As a result of using permutation to obtain empirical p-value, most of these methods
could control Type I error rate well, although some are conservative. However, the methods varied greatly in terms
of power and running time, with the PLINK truncated set-based test being the most powerful and KGG being the
fastest.
Conclusions: Raw data-based algorithms, such as those implemented in PLINK, are preferable for GWAS pathway
analysis as long as computational capacity is available. It may be worthwhile to apply two or more pathway
analysis algorithms on the same GWAS dataset, since the methods differ greatly in their outputs and might provide
complementary findings for the studied complex disease.
Background
Simple single-marker tests used in genome-wide associa-
tion studies (GWAS) have contributed to the discovery
of many loci responsible for the variation observed in
complex traits or disorders [1-3]; nevertheless, they are
also criticized for their stringent significance threshold
[4] and disregard of prior knowledge, which might lead
to Type II errors, that is, not detecting real effects.
Recently, a number of complementary approaches have
been developed to prioritize susceptibility genes of com-
plex diseases and increase power, of which meta-
analysis, epistasis analysis and GWAS pathway analysis
(GWASPA) are typical ones and already widely applied
[5].
Biological pathways, which are actually series of
actions among molecules in a cell that lead to a certain
product or a change in a cell [6], are usually identified
by experimental approaches [7,8] and then revised with
bioinformatical mining tools [9]. Shared across different
organisms, pathways play an important role in metabo-
lism, gene regulation and signal transduction [10]. With
genetic or environmental perturbations, some normal
pathways might become dysfunctional and then contri-
bute to complex diseases [11]. Pathway analysis for
complex disease, also known as gene-set analysis, origi-
nated with genomic expression studies [12]; one of the
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sentation analysis by hypergeometric test, while the
other is gene-set enrichment analysis (GSEA) using Kol-
mogorov-Smirnov-like test statistics [13,14]. Since Wang
et al. [15] first applied GSEA to GWAS data, more and
more algorithms for performing genome-wide pathway
analysis for SNP-chip datasets have emerged [16-19].
The PLINK set-based test utilizes average test statistics
of groups of independent and/or truncated SNPs to pro-
vide a pathway-level test [17]; gene set ridge regression
in association studies (GRASS) assesses joint association
of pre-selected Eigen-SNPs for each gene in a candidate
pathway with disease [18]; improved GSEA and associa-
tion list Gene-ontology (GO) annotator (ALIGATOR)
are two algorithms which utilize SNP-level test statistics
or p-values in order to reduce computation cost over
raw data-based methods [19,20]. These different algo-
rithms could be categorized according to type of input
data (raw data or summary statistics), counts of analysis
stages (one or two stage), or basic hypothetical tests
(competitive or self-contained) [16]. The difference
between GWAS pathway analysis and classical pathway
analysis in genomic expression studies lies in whether a
gene-based score is directly provided or not. Previous
research on multi-allelic association tests or gene-based
tests, which always produce gene-level scores indirectly,
provide a good bridge for pathway analysis on individual
SNPs [21-23]. Among them, GATES is a rapid and
powerful procedure for getting gene-based statistics
which sometimes serve as a prerequisite for further
advanced analysis [22].
Though several methods have already been proposed,
there is no consensus as to the best method for con-
ducting a GWASPA, especially when the underlying
causal mechanism for disease at the functional level is
not yet clear [16,24]. Results discrepancies among differ-
ent methods on the same dataset might arise due to dif-
ferent mapping strategies from SNPs to pathways, or an
algorithm’s power of detecting susceptibility pathways,
as well as incompatible pathway databases used [24].
Wang et al. [16] discussed the basic issues, main proce-
dures and challenges involved in method development
for GWASPA, but did not give a guideline of how to
apply these methods from a practical perspective. Chen
et al. [18] did compare the performance of different
methods when evaluating the GRASS algorithm, but the
simulation scenarios were designed for only one candi-
date pathway, and therefore need to be extended by
examining both comprehensive simulated and real data-
sets on a genome-wide scale. Ballard et al. [25] illu-
strated the advantage of the random set method over
the hypergeometric test for pathway analysis by analyz-
ing three GWAS samples for Crohn’s Disease (CD);
however, they did not include any summary statistics-
based algorithms which are becoming more and more
popular [26].
As one of those complex diseases investigated at the
earlier stage of GWAS [27], evidence for disease-causal
variants, genes or even pathways related to CD are
increasingly provided [3,25,27-29]. Meanwhile, the CD
dataset from the Wellcome Trust Case Control Consor-
tium (WTCCC) [30], which is openly available, has been
repeatedly utilized and extensively explored by a variety
of approaches [29,31,32]. This relatively abundant
knowledge makes the WTCCC CD dataset a good test-
ing sample for evaluating the performance of newly
developed methods. Therefore, in this study, we imple-
mented two summary statistics-based algorithms in an
open-source tool named Knowledge-Based Mining Sys-
tem for Genome-Wide Genetic Studies (KGG) [22]; and
then compared the performance of these two methods
with another five existingm e t h o d su s i n gt h eW T C C C
CD dataset, to evaluate the characteristics of the various
methods, including Type 1 error, power and running
time.
Methods
Algorithms
KGG is an open-source Java package developed for
whole genome gene-based analysis, pathway analysis and
protein-protein network analysis. Currently, it contains
two classical algorithms for performing downstream
pathway analysis after getting gene-level statistics by
GATES [22], a novel gene-based method previously
implemented in KGG. Formula 1 showed core idea of
GATES, while formula 2 and 3 were basics of Simes’
test [33] and hypergeometric test [34]; KGG would
finally produce corresponding pathway-level results after
running GATES-Simes or GATES-Hyper.
PG = min
j
{
meP(j)
me(j)
} (1)
Note: P (j) are the ordered j
th p-values (j from 1 to M)
of the individual SNPs mapped to gene G; me is the
effective number of independent SNP p-values among
all M SNPs, after accounting for the LD structure
among these M SNPs; me(j) is the effective number of
independent SNP p-values among the top j SNPs, after
accounting for the LD structure among these j SNPs.
PGATES−sime(A) = min
i
{
kPG(i)
i
} (2)
N o t e :A s s u m ekg e n e sm a p p e dt op a t h w a yA ,P G( i )
calculated by GATES, is the i
th ordered gene p-value (i
from 1 to k) among all k genes in pathway A.
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Note: N is the total number of genes in the whole
gene list; Q is the number of those N genes in the path-
way A; n is the total number of genes passing gene p-
value threshold; and q is number of genes in pathway A
out of those n genes.
Among the other five selected algorithms, only Aliga-
tor takes SNP-level summary statistics as input as
GATES-Simes and GATES-Hyper does; for Aligator, a
gene is treated as significant if it contains at least one
SNP with p-value below predefined threshold. Each
pathway is then tested for whether it contains more sig-
nificant genes than expected by chance [20]. GSEAforG-
WAS selects the maximum SNP-level test statistic to
represent a gene-level score, and then applies a weighted
Kolmogorov-Smirnov running sum of competitive path-
ways to evaluate whether a particular pathway is
enriched with top ranking genes or not [15]. GRASS cal-
culates gene scores by combining regularized beta coef-
ficients of pre-selected Eigen SNPs, following by getting
the pathway-level score from standardized gene-level
scores [18]. Both PLINK-Ave and PLINK-Max adopt the
idea of a “set-based test”, which computes a pathway
level score directly from averaging SNP-level test statis-
tics. After pruning SNPs in high LD, PLINK-Max only
uses the top SNP in a pathway, but PLINK-Ave selects a
few SNPs (default setting is up to the top 5 SNPs with
p-value smaller than predefined threshold) [17]. All of
the above five algorithms need to evaluate significance
for pathway association with disease by permutation,
and we permuted 1000 times for all methods.
Evaluation data
880 canonical pathways (originated from KEGG [35],
BioCarta [36] and Reactome [37]) which been manually
curated by biology experts, were collected from the
MsigDB database [38]. In comparison with Gene Ontol-
ogy (GO) [39], which collects more broad functional
categories in a hierarchical pattern, these canonical
pathways represent relatively well-defined known biolo-
gical pathways [40]. To further reduce pathway-level
heterogeneity, we only included pathways which con-
tained between 10 and 300 genes, which filtered out 27
pathways. Another potential CD causal pathway “IL12-
IL23” [16,29] which was not in the database was also
included, thus making the total number of selected can-
didate pathways to be 854. A survey of pathway size dis-
tribution, gene membership and overlapping ratio per
pair-wise pathways was conducted by simple calculation
using the ‘Table’ function in R. The WTCCC Crohn’s
Disease GWAS dataset was downloaded from the
WTCCC website. Adopting the same quality control
procedures as in the flagship publication [27], we
included 1,748 CD patients as cases and 1,480 healthy
individuals from the 1958 Birth Cohort [27] as controls.
All the samples were genotyped with the Affymetrix 500
K chips. In total, 391,422 SNPs remained after quality
control procedures for markers (minor allele frequency
(MAF) > 0.05, Hardy-Weinberg equilibrium (HWE) p >
0.001, etc). Further selection of SNPs in or near (within
5 kb upstream or downstream) genes in the 854 canoni-
cal pathways resulted in 61,340 SNPs for subsequent
pathway analysis. In order to run those summary statis-
tics-based algorithms, we used PLINK (logistic regres-
sion model) to calculate SNP-level summary statistics
(beta coefficient, odds ratio, p-value, etc.) with a general
genomic control as population stratification adjustment.
Due to lack of benchmark pathways for Crohn’s Disease,
we chose a subset of pathways from the 854 by enrich-
ment analysis with GeneTrial [41], setting 93 candidate
genes [3] previously reported for CD as input. This sub-
set of pathways which were potentially associated with
Crohn’s disease was then recorded as list 1.
Comparison of performance
We created a permuted dataset by assigning randomly
shuffled case/control labels to original genotypes from
the WTCCC CD dataset. Four algorithms (PLINK-AVE,
PLINK-MAX, GSEAforGWAS and GRASS) were
adopted to perform pathway analysis on this raw per-
muted data when the other three algorithms (GATES-
Simes, GATES-Hyper and Aligator) on SNP level sum-
mary statistics from logistic regression analysis of raw
simulated data. Each algorithm would produce a set of
pathway level p-values. Since the null hypotheses
assumed that no pathways were enriched by disease-sus-
ceptibility SNPs or genes for this simulated dataset, we
estimated Type I error for each algorithm empirically by
calculating the proportion of pathways with nominal p-
values smaller than the critical threshold (set at 0.05)
out of all 854 pathways. One sample Kolmogorov-Smir-
nov tests were performed to investigate whether
observed pathway p-values followed a (0, 1) uniform dis-
tribution or not. Then algorithms which had an appro-
priate type I error rate were applied to the original CD
dataset so as to prioritize potential causal pathways. In
order to conduct these comparisons fairly, the same
value was set when a predefined threshold was needed.
False discovery rates (FDR) [42] were computed from
pathway p-values produced by different algorithms, and
pathways with FDR smaller than 0.05 were treated as
significantly associated with CD and then marked as
pathway list 2. Hypergeometric tests were conducted to
check whether the number of overlapping pathways
between list 1 and list 2 was greater than expected by
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pathway from different algorithms were also recorded
and compared. Therefore, power of detecting real asso-
ciated pathways for all 7 algorithms could be quantified
by three indices: number of significant pathways, p-
values from the hypergeometric test, and significance
level for IL12-IL23 pathway. In addition, impact of vary-
ing p-value threshold and LD pruning cut-off on power
were investigated with GATES-Hyper and PLINK-AVE,
since such impact for other algorithms was either not
necessary or addressed before [16,18,20].
Results
Survey on MsigDB canonical pathways
Table 1 presents characteristics of the 854 selected can-
didate pathways. Most of these pathways contain
between 10 and 100 genes. Overlapping genes among
pairs of pathways was less than 1 percent, allowing us to
assume that the pathways were effectively independent,
as required for GWASPA. However, investigation of
genes mapping to pathways (also Table 1) showed that
less than 30% of total pathway-included genes were
unique to one pathway, while a few genes can even be
covered by more than 100 different pathways. Pathway
enrichment analysis for 93 candidate genes of CD
revealed that 28 candidate pathways might be involved
in causation of this disease (Additional File 1: Table S1).
Literature evidence supported that 18 of these 28 path-
ways have good potential to associate with CD (also see
Additional File 1: Table S1), though not all validated by
experiments yet.
Type I error rate comparison
Quantile-quantile (QQ) plots [43] for original SNP p-
values and GATES-produced gene p-values in a permu-
tated dataset are shown in Figure 1. No SNPs or genes
mapping to selected pathways were apparently deviated
from the theoretical straight line of a uniform distribu-
tion for this permuted dataset, indicating that the tests
behave correctly under the null and the permutation
procedure has eliminated all effects. Table 2 contains
estimates of Type I error (at family wise error rate 0.05)
for seven different GWASPA algorithms. Most of them
were conservative since Type I error rates were below
0.05, two even smaller than 0.02 (GRASS, GATES-
Hyper). This tendency was verified by one sample K-S
test for (0, 1) uniform distribution (also Table 2) and
QQ plot for pathway p-values (Figure 2).
Power and CD susceptibility pathways
A QQ plot of SNP-based test statistics from the
WTCCC Crohn’s Disease dataset shows that a bunch of
individual SNPs and a few genes were significantly asso-
ciated with CD (Figure 3). Table 3 presents three indica-
tors of power of different algorithms for detecting
hidden susceptibility pathways. Consistently, PLINK-Ave
appears to be the most powerful algorithm, as it pro-
duced more significant pathways that overlapped with
previously known pathways than any other algorithm
(Table 3). However, it takes more consideration when
running PLINK-Ave, which is affected by flexible setting
of LD and p-value truncation cut-offs (Additional File 1:
Table S2). In general, summary statistics-based algo-
rithms (GATES-Hyper, GATES-Simes and Aligator) had
less power than those raw data-based algorithms, and
use of average statistics (PLINK-Ave and GRASS) was
more powerful than relying on the top statistics within a
given pathway (PLINK-Max and GSEAforGWAS). Only
one pathway was detected in common by PLINK-Ave,
GRASS and GSEAforGWAS, but there might be around
80 pathways in total possibly related to CD (Additional
File 1: Table S3).
Summary of running time and computing platform
Table 4 presents a summary of running times for all
seven algorithms. Generally, algorithms with summary
statistics as input were much faster than those utilizing
raw data. Pathway analysis by GATES-Simes and
GATES-Hyper could complete within one hour on a
typical desktop computer. The time spent on
Table 1 Summary of selected Canonical pathways
Pathway size by gene Pathway overlapping Gene mapping to pathway
Range Proportion Range Proportion
1 Range Proportion
> = 10, < 20 36% 0 84% Unique 26.20%
> = 20, < 100 55% > 0, < 0.01 2.10% > = 2, < 10 58.50%
> = 100, < 200 7.70% > 0.01, < 0.1 11.30% > = 10, < 100 15.10%
> = 200, < 300 1.30% > 0.1, < 0.5 2.50% > = 100 0.20%
> 0.5 0.10%
Note 1: consider all possible pairs from of 854 canonical pathways; define the ratio as sharing count of genes out of all different genes for one pair of pathways
(union overlap).
A survey on 854 selected candidate pathways was conducted in order to investigate the characteristics of pathway size, pair-wise pathway overlap and gene
allocation. Pathway size was measured by number of genes contained in the pathway; pathway overlapping was defined by the union overlapping ratio for one
pair of pathways; gene allocation was counted as the number of pathways the genes belong to.
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marker LD information by KGG took most of the hour.
Aligator and GRASS are both implemented in the R-
SNPath package on a multi-core cluster, taking advan-
tage of parallel computation. GSEAforGWAS was exe-
cuted by the GenGen program following suggestion for
parallel computation on their website–distributing per-
mutations on four different nodes (each 250 times).
Discussion
It has been suggested that multiple genes in immune
system functional pathways, especially those containing
different Interleukin factors, might be involved in cau-
sation of Crohn’s Disease [28,29]. Our findings of CD
pathways across different algorithms also fall mostly
into the category of immune response related path-
ways, though the number of significant pathways var-
ied greatly for each individual algorithm. Likely, these
differences are due to differences in four factors. The
first is null hypothesis differences between self-con-
tained tests and competitive tests [44,45]. PLINK-Ave,
PLINK-Max, GRASS and GATES-Simes, which are
self-contained tests (see table 4), assume that a path-
way does not contain any significant SNPs or genes.
But GATES-Hyper, Aligator and GSEAforGWAS are
all based on competitive tests (see table 4), which aims
to test whether genes in one pathway are enriched
with a greater number of associated SNPs. The second
contributor to the differences observed is differences
in test statistic construction. PLINK-AVE and GRASS
both applies an “average” concept which combines evi-
dence of selected SNPs or genes to identify pathways
with more overall association signal, but PLINK-Max,
GATES-Simes, GATES-Hyper, Aligator and GSEA-
forGWAS all use a “maximum” concept when comput-
ing pathway score from SNP scores directly or
indirectly, relying on the most associated SNP in a
pathway. It is likely that the underlying causal mechan-
ism for CD involves more pathways covering moderate
effect SNPs than simply a few pathways with top SNP
hits only [21], implying that many more SNPs than we
can identify individually contribute to disease. A third
contributor to the differences observed is whether
genes are treated as an intermediate bridge from SNPs
and pathways in a two-stage approach. Though it has
Figure 1 QQ plot for SNP/gene p-values of a permuted CD dataset. SNPs were divided into inside-of-genes and outside-of-genes according
to their physical coordinates on the hg18 genome. Gene p-values were calculated by KGG, using the GATES algorithm.
Table 2 Type I error rate for seven algorithms
Algorithms Type I error
(0.05)
K-S test
(two-sided)
GATES-Simes 0.043 < 2.2e-12
GATES-Hyper 0.016 5.4e-09
Aligator 0.032 2.6e-3
GRASS 0.018 5.1e-12
GSEAforGWAS 0.016 < 2.2e-16
PLINK-Ave 0.055 3.1e-06
PLINK-Max 0.036 9.5e-05
Two indices (Type I error and K-S test) were used to check whether those
algorithms produced more false positive results than by chance. Type I error
was calculated as proportion of pathways with nominal p-values < 0.05. The
two-sided Kolmogorov-Smirnov test was used to investigate whether p-values
from each algorithm follow the theoretical (0, 1) uniform distribution.
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more robust and powerful than one stage pathway ana-
lysis [46], our analyses don’t support this, with the
PLINK set-based test found to be superior to other
gene-based algorithms. Finally, different strategies of
handling LD structure between SNPs can also explain
part of the variation in performance. Pruning SNPs in
high LD (PLINK), choosing Eigen SNPs by principal
component analysis (GRASS and KGG), or focusing
only on the top SNP (Aligator and GSEAforGWAS),
Figure 2 QQ-plots for GWAS pathway p-values of seven algorithms for permuted datasets. P-values for all 854 candidate pathways
produced by each algorithm were plotted against their expected values from a (0, 1) uniform distribution.
Figure 3 QQ plot for SNP/gene p-values from the CD dataset. SNPs were divided into inside-of-genes and outside-of-genes according to
their physical coordinates on hg18 genome. Gene p-values were calculated by KGG, using the GATES algorithm.
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SNP dependency, but may perform differently.
Due to complexity caused by SNP, gene, and pathway
relationships, re-sampling strategies like permutation are
always utilized to derive an empirical distribution for
test statistics to evaluate the significance of candidate
pathways. However, it comes with a cost of time and
memory. Usually two approaches are used to lighten the
computational burden, either a revised adaptive or opti-
mal permutation of raw genotype/phenotype data
[46,47] or a permutation of SNP or gene labels in sum-
mary statistics data [48]. We showed that GATES-Hyper
and GATES-Simes implemented in KGG were much
faster than those permutation-based algorithms since
both of them used approximation for p-value distribu-
tion. Clearly, the advantages of GWASPA over genomic
expression studies or traditional laboratory works (such
as knock out mouse and cultured cells) [7,8] are appar-
ent in terms of time and economy and can be used to
guide these further studies.
There are also some limitations of our study. While
the WTCCC CD dataset is an ideal model GWAS, the
performance of GWASPA algorithms may not be as
good with other datasets, where studies are smaller and
less is known regarding function at the outset. We
recommend applying two or more algorithms from dif-
ferent categories (self-contained versus competitive,
average versus maximum and one-stage versus two-
stage) in practice, especially when we cannot readily dis-
tinguish the scenario in which various susceptibility var-
iants confer moderate risk to disease versus the scenario
in which a major effect variant in a pathway plays a
dominant role in complex diseases [15,20]. In addition,
we set a fixed threshold for SNP or gene p-value trunca-
tion when including them for pathway analysis by
PLINK-Ave, Aligator, and GATES-Hyper, but this cut-
off is somewhat arbitrary and the choice made can influ-
ence results dramatically. Moreover, the FDR method
was applied to correct for multiple testing and deter-
mine significance on pathway level, since almost no
pathway p-values would survive Bonferroni adjustment
[49]. Nevertheless, we think it was still reasonable for
comparing performances of different algorithms, since
we applied the same standards to all methods tested
[24]. Lastly, none of these algorithms took differences in
pathway structure stored in the original BioPAX or
SBML format into consideration [50], but treated them
as plain text containing independent gene symbols,
when in fact any gene can be a member of multiple
pathways. This drawback is handling by more advanced
statistical methods like mixed-effect models and Baye-
sian networks, which facilitates modelling of gene-gene
overlapping, interaction and correlation as well as net
gene effect within the same pathway [51,52].
Conclusions
GWAS pathway analysis, which prioritizes candidate
pathways associated with complex disorders, could serve
as an important complement to individual SNP analysis
and gene-based analysis. Though all algorithms selected
in this study do not have inflated Type I error rates,
they vary greatly in terms of power and running time.
The PLINK truncated set-based test was the most
Table 4 Running time summary
Algorithm Software Input Null Hypothesis Computer configuration Runtime
GATES-Simes KGG
1 Summary statistics Self contained Intel Core 2 Quad CPU Q9400 2.67 GHz,
4 GB RAM (desktop computer)
30 mins
5
GATES-Hyper KGG Summary statistics Self contained As above 30 mins
5
Aligator R-SNPath
2 Summary statistics Competitive Intel XEON 2 six-core x5670 2.93 Ghz,
128 GB RAM (cluster)
2 hours
GRASS R-SNPath Raw data Self contained As above 14 days
GSEAforGWAS GenGen
3 Raw data Competitive As above 2 days
PLINK-Ave PLINK
4 Raw data Self contained As above 40 hours
PLINK-Max PLINK Raw data Self contained As above 40 hours
Notes: 1, URL for KGG at http://bioinfo.hku.hk:13080/kggweb/home.htm; 2, URL for SNPath package at http://linchen.fhcrc.org/grass.html; 3, URL for GenGen
program at http://www.openbioinformatics.org/gengen/; 4, URL for PLINK at http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml; 5, excluding time spent
building analysis genome (see KGG online manual).
Table 3 Power indication from CD dataset
All candidate pathways IL12-IL23
pathway
Algorithms No. of
sign
1
No. of
known
2
Hyper-
test
3
p-
value
FDR
GATES-Simes 4 3 1.20e-4 0.009 0.154
GATES-Hyper 0 0 – 0.005 0.493
Aligator 4 2 0.006 0.595 1
GRASS 41 3 0.146 0.031 0.158
GSEAforGWAS 10 2 0.04 0.004 0.118
PLINK-Ave 40 8 1.77e-5 0.002 0.043
PLINK-Max 0 0 – 0.006 0.155
Notes: 1, significance was defined as FDR for individual pathway smaller than
0.05; 2, no. of overlapping pathways between significant pathways in this
study and previous known pathways for CD; 3, hyper-geometric test.
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rithms implemented in KGG were the fastest. However,
raw data-based algorithms should be preferred for
GWAS pathway analysis as long as computation capa-
city is available, since they preserve the intact data
structure and tend to be more powerful than summary
statistics-based algorithms. When underlying disease
causal mechanism is ambiguous, which is common for
complex diseases, it is worthwhile to apply two or more
pathway analysis algorithms on the same GWAS dataset.
Availability and Requirements
KGG is implemented using Java; therefore a Java Run-
time Environment (JRE) is required to run KGG. Cur-
rently, installation of JRE and KGG are supported for
Windows, Mac OS × and Linux. Three command files
(run.win.bat, run.mac.sh and run.linux.sh) are provided
for users to run KGG easily. A graphical user interface
will automatically appear once initiating the command
file. Documentation, source code, and precompiled bin-
aries can be downloaded from http://bioinfo.hku.
hk:13080/kggweb/home.htm.
Additional material
Additional file 1: Potential CD-associated pathways by different
methods. Table S1. Positive pathways for Crohn’s disease from
enrichment analysis of 93 CD susceptibility genes. This table contains
28 enriched pathways (FDR < 0.05, hypergeometric test) from GeneTrail
analysis. These pathways are treated as positive pathways for CD in this
study. Table S2. Number of significant pathways (FDR < 0.05)
detected by PLINK-Ave and GATES-Hyper algorithm with different
LD and p-value threshold setting. This table shows impact of varying
LD pruning and p-value threshold on detecting significant pathways for
Crohn’s disease. Table S3. Overlapping between pathways detected
by different raw data based algorithms. This table presents significant
pathways (FDR < 0.05) detected by PLINK-AVE, GRASS and GSEAforGWAS.
The overlap between each pair of algorithms and also with positive
pathways is illustrated by ‘Yes’ or ‘No’.
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